TPI-1 NEW
| Price | $48 | $70 | $117 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: TPI-1 | CAS No.: 79756-69-7 |
| Purity: 99.79% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | TPI-1 |
| Description | TPI-1 is a SHP-1 inhibitor. |
| Kinase Assay | Jump-In TI CHO-K cells stably expressing WT or mutant S1P3 are serum-starved for 4 hrs. They are then incubated at 4 °C for 30 min in the binding buffer containing 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 15 mM NaF, 0.5 mM EDTA, 1 mM Na3VO4, 0.5% fatty acid-free bovine serum albumin, and protease inhibitor mixture with 0.1 nM [33P]S1P and increasing concentrations of S1P, SPM-242, or CYM-5541. Cells are washed three times with cold binding buffer. Cell-bound radioactivity is measured by lysing the cells with 0.5% SDS followed by liquid scintillation counting. The raw data is normalized so that the level of [33P]S1P bound to each cell line (WT or mutant) in the absence of competing ligand is referenced as 100% for its own cell line[1]. |
| In vitro | SHP-1 has been identified as a promising target for cancer therapy. TPI-1, starting at an effective concentration of 10 ng/mL, selectively enhances the phosphorylation of SHP-1 substrates (notably pLck-pY394) in Jurkat T cells, without significantly affecting pERK1/2 or pLck-pY505 levels. Moreover, TPI-1 promotes the induction of IFNγ+ cells both in mouse spleen and human peripheral blood[1], demonstrating its potential selectivity and therapeutic efficacy in a cellular context. |
| In vivo | TPI-1 effectively suppresses the growth of B16 melanoma tumors in mice through a mechanism reliant on T cells when administered orally at tolerable doses, yet it demonstrates minimal impact on B16 cell proliferation in vitro. Additionally, TPI-1 enhances the levels of pLck-pY394 and IFNγ+ cells in mice, further contributing to its anti-tumor activity. Notably, TPI-1 also restricts B16 tumor expansion and extends the survival of mice bearing tumors when given as a subcutaneously tolerated agent[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (177.81 mM) |
| Keywords | TPI-1 | Inhibitor | inhibit | Phosphatase |
| Inhibitors Related | Nimodipine | Hydrocortisone | Mifepristone | β-Glycerophosphate disodium salt pentahydrate | Dexamethasone acetate | Tartaric acid disodium dihydrate | Cyclosporine | Stearic acid | Cis-5-Norbornene-exo-2,3-dicarboxylic Anhydride | Prednisone acetate | Desonide | Corticosterone |
| Related Compound Libraries | Nuclear Receptor Compound Library | Glycometabolism Compound Library | Bioactive Compound Library | Inhibitor Library | Endocrinology-Hormone Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Phosphatase Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-05 | |
| $0.00/1BOX |
VIP1Y
|
Shanghai Affida new material science and technology center
|
2024-05-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY